8,400 Shares in LeMaitre Vascular, Inc. $LMAT Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 2nd quarter, Holdings Channel.com reports. The fund bought 8,400 shares of the medical instruments supplier’s stock, valued at approximately $806,000.

Several other hedge funds also recently bought and sold shares of LMAT. Kennedy Capital Management LLC lifted its position in shares of LeMaitre Vascular by 14.8% in the fourth quarter. Kennedy Capital Management LLC now owns 247,907 shares of the medical instruments supplier’s stock worth $20,105,000 after purchasing an additional 32,040 shares in the last quarter. Wakefield Asset Management LLLP acquired a new position in LeMaitre Vascular during the fourth quarter worth $1,130,000. Vanguard Group Inc. grew its position in LeMaitre Vascular by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after purchasing an additional 21,946 shares in the last quarter. Riverbridge Partners LLC bought a new position in LeMaitre Vascular in the first quarter valued at $11,528,000. Finally, M&T Bank Corp increased its stake in LeMaitre Vascular by 2,240.5% in the 4th quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after buying an additional 381,061 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on LMAT. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, August 14th. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Citizens Jmp raised their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Hold” and an average price target of $110.60.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $83.87 on Thursday. The firm has a market capitalization of $1.92 billion, a P/E ratio of 29.43, a price-to-earnings-growth ratio of 2.35 and a beta of 0.53. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40. The firm’s fifty day moving average price is $94.78 and its two-hundred day moving average price is $99.72. LeMaitre Vascular, Inc. has a 1 year low of $78.65 and a 1 year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The firm had revenue of $70.38 million during the quarter, compared to the consensus estimate of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business’s revenue was up 9.6% on a year-over-year basis. During the same period last year, the business earned $0.60 EPS. As a group, research analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 35.09%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.